These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12712938)

  • 1. T-20: most expensive AIDS drug ever at $25,000 per year?
    James JS
    AIDS Treat News; 2003 Mar; (389):6-7. PubMed ID: 12712938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
    Sharp M; Camp R
    GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug cost. States concerned about Fuzeon.
    AIDS Policy Law; 2003 Apr; 18(7):5. PubMed ID: 12728848
    [No Abstract]   [Full Text] [Related]  

  • 4. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 5. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 6. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 7. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug pricing. High price of Fuzeon, other recent drugs sets tough pricing precedent.
    AIDS Policy Law; 2005 Jul; 20(14):4. PubMed ID: 16108122
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA news. Price criticized for new anti-HIV drug.
    AIDS Alert; 2003 May; 18(5):67-8. PubMed ID: 12751460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 12. New class of HIV drugs shows promise.
    Dove A
    Nat Med; 2001 Dec; 7(12):1265. PubMed ID: 11726950
    [No Abstract]   [Full Text] [Related]  

  • 13. New class of medications approved for advance HIV.
    FDA Consum; 2003; 37(3):5. PubMed ID: 12793380
    [No Abstract]   [Full Text] [Related]  

  • 14. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 15. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 16. Enfuvirtide, a new treatment for HIV infection.
    Moledina S; Boucher M
    Issues Emerg Health Technol; 2003 Oct; (50):1-6. PubMed ID: 14594020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 18. Fresh data on new anti-HIV drugs presented in Durban.
    Leibovich M
    Posit Living; 2000 Aug; 9(7):16-7. PubMed ID: 12492026
    [No Abstract]   [Full Text] [Related]  

  • 19. A T-20 diary.
    Gormley F
    GMHC Treat Issues; 2002 Mar; 16(3):6-7. PubMed ID: 12004799
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.